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We  report  a case  of  torsades  de pointes  (TdP)  induced  by  donepezil  without  QT  prolongation.  An  86-
year-old  woman  was  admitted  to  our hospital  because  of  a  syncopal  attack.  She had  been  treated  for
Alzheimer’s  disease  with  donepezil.  Initial  12-lead  electrocardiogram  showed  atrial  ﬁbrillation  and
normal  corrected  QT  interval.  After  admission,  atrial  ﬁbrillation  spontaneously  recovered  to normal
sinus  rhythm  on electrocardiographic  monitoring.  On  the  second  day,  electrocardiographic  monitor-
ing  documented  TdP.  We  discontinued  donepezil  immediately.  After washout  of donepezil,  TdP  was
not observed  again.  Corrected  QT  interval  was  normal  throughout  hospitalization.  This  case  suggestsentricular arrhythmia that  donepezil  may  cause  life-threatening  ventricular  arrhythmias  without  QT  prolongation.  Even  if  cor-
rected  QT  interval  is  normal  in  patients  taking  donepezil  and  experiencing  symptoms  associated  with
TdP,  electrocardiographic  monitoring  is recommended.
<Learning  objective:  Donepezil  may  cause  life-threatening  ventricular  arrhythmias  without  QT  prolon-
gation.  Even  if corrected  QT interval  is  normal  in  patients  taking  donepezil  and  experiencing  symptoms
associated  with  torsades  de  pointes,  electrocardiographic  monitoring  is  recommended.>
© 2013  Japanese  College  of Cardiology.  Published  by Elsevier  Ltd.  All  rights  reserved.ntroduction
“Proarrhythmia” or “arrhythmogenicity” indicates the capacity
f a cardiac or noncardiac drug to aggravate an existing arrhythmia
r provoke a new arrhythmia [1].
Donepezil is an acetylcholinesterase inhibitor used widely for
he treatment of Alzheimer’s disease. Side effects of donepezil are
asically cholinergic dependent. The most common adverse events
re nausea, diarrhea, malaise, dizziness, and insomnia. Donepezil
s considered a safe agent with few adverse effects on the cardio-
ascular system. However, since the heart is rich in cholinesterase,
ts cholinergic effects could generate serious cardiac disorders such
s bradycardia, atrioventricular block, and QT prolongation [2]. QT
rolongation may  lead to torsades de pointes (TdP), a polymorphic
entricular arrhythmia that can progress to ventricular ﬁbrillation
nd sudden death. The present report describes a rare case of TdP
nduced by donepezil without QT prolongation.∗ Corresponding author. Tel.: +81 834 28 4411; fax: +81 834 29 2579.
E-mail address: hytch@hotmail.co.jp (Y. Hadano).
878-5409/$ – see front matter © 2013 Japanese College of Cardiology. Published by Else
ttp://dx.doi.org/10.1016/j.jccase.2013.05.004Case report
An 86-year-old woman  was admitted to our hospital because
of a syncopal attack. On admission, she was alert and asymp-
tomatic. She had no history of cardiovascular disease or previous
syncope, and no family history of cardiovascular disease or sud-
den death. She had been treated for Alzheimer’s disease with
donepezil 5 mg/day for three years by her home physician. She
also had hypertension, which had been treated with amlodipine
5 mg/day. Because she had lived in a nursing home, these drugs
were administered to her by nurses without fail. She had no symp-
toms of acetylcholine poisoning, such as miosis or dysuria. Her
blood pressure was 124/60 mmHg. She had neither cardiac mur-
mur  nor symptoms of heart failure. Neurological ﬁndings, chest
radiograph, and transthoracic echocardiogram were unremark-
able. Initial 12-lead electrocardiogram showed atrial ﬁbrillation
(heart rate, 75 beats/min) and normal corrected QT (QTc) inter-
val (QT 390 ms;  QTc 436 ms)  (Fig. 1A). The interval between
the peak and the end of the T wave (Tp–Te) was 100 ms; and
corrected Tp–Te interval was 112 ms.  She had not undergone 12-
lead electrocardiogram before donepezil medication. Blood tests
were within normal limits (potassium 3.69 mEq/l, magnesium
2.0 mg/dl, calcium 8.7 mg/dl, aspartate aminotransferase 20 IU/l,
vier Ltd. All rights reserved.
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tFig. 1. Changes in 12-lead electrocardiogram. (A) Admission, (B) just after the doc
lanine aminotransferase 10 IU/l, blood urea nitrogen 14.6 mg/dl,
reatinine 0.85 mg/dl).
After admission, she was prescribed bed rest. Because her blood
ressure dropped to 98/58 mmHg, amlodipine was halted. At mid-
ight, atrial ﬁbrillation spontaneously recovered to normal sinus
hythm on electrocardiographic monitoring and we  only detected
 short pause (1.4 s). Several hours later, in the daytime on the sec-
nd day, electrocardiographic monitoring documented TdP when
he lay on the bed (Figs. 2 and 3). This arrhythmia was sustained
or 10 s and terminated spontaneously without medication or direct
urrent cardioversion. Repeat 12-lead electrocardiogram revealed
ormal sinus rhythm (heart rate, 78 beats/min) and normal QTc
nterval (QT 380 ms;  QTc 433 ms)  (Fig. 1B). We  started an intra-
enous infusion of lidocaine at the rate of 1 mg/min. Although we
ould not measure donepezil concentration in her blood, we discon-
inued donepezil immediately. We  detected TdP total ﬁve times for
 h. Every TdP terminated spontaneously within 30 s, without other
rugs or direct current cardioversion. She experienced no syncope,
ut she was assumed to have fallen because of Adams–Stokes syn-
rome due to TdP. After washout of donepezil, we  found neither
dP nor worsening of dementia. We  performed catheter examina-
ion 10 days after the withdrawal of donepezil and 7 days after
he withdrawal of lidocaine. Coronary arteriogram demonstrated
o signiﬁcant stenosis of coronary arteries. Programmed ventri-
ular stimulation could not induce ventricular ﬁbrillation. As we
onﬁrmed paroxysmal atrial ﬁbrillation again, we selected medical
ollow-up with bisoprolol and metildigoxin for paroxysmal atrial
brillation. In the serial electrocardiogram follow up, QTc inter-
al was normal. Twelve-lead electrocardiogram on the day before
ischarge noted normal sinus rhythm (heart rate, 64 beats/min)
Fig. 1C). Tp–Te interval was 80 ms;  and corrected Tp–Te interval was
3 ms.  She was discharged in a stable condition without adminis-
ration of donepezil.
Fig. 2. Electrocardiographic monitoring on the setation of torsades de pointes on the second day, and (C) the day before discharge.
Discussion
Cardiac and noncardiac drugs have been known to facilitate
proarrhythmia [1]. Drugs that are generally identiﬁed to confer a
risk of TdP include antiarrhythmic agents, inotropic agents, antibi-
otic agents, antipsychotic agents, and antihistamines. Most of the
drugs produce either QT prolongation or an increase in adrenergic
tone.
Donepezil works at the level of the central nervous system
and is highly speciﬁc for neural acetylcholinesterases. This speci-
ﬁcity minimizes peripheral adverse effects in therapeutic doses.
A previous study found that donepezil therapy for each dose
has no signiﬁcant effect on electrocardiographic parameters,
including heart rate, PR, QT and QTc interval, and QRS dura-
tion, in elderly patients with Alzheimer’s disease compared to
baseline [3]. It was  demonstrated that donepezil has neither neg-
ative chronotropic and arrhythmogenic effects nor hypotensive
effects. However, it has rarely been reported that bradycardia,
atrioventricular block, and TdP were seen in patients receiving
donepezil [2].
In the current case, plasma donepezil level was  not mea-
sured. However, we  conﬁrmed no TdP after washout of donepezil.
Therefore, we concluded that TdP might be induced by donepezil.
Donepezil has a terminal elimination half-life of 50–70 h in young
volunteers; in elderly volunteers, the half-life of donepezil is
extended to over 100 h. High concentration of donepezil could
result in TdP.
Cholinesterase is distributed abundantly in the heart and its
inhibition may  affect cardiac function, especially in elderly patients.
Donepezil inhibits acetylcholinesterase and increases the concen-
tration of acetylcholine by preventing degradation. High levels of
acetylcholine may  lead to the development of ventricular arrhyth-
mias via vagal tone stimulation [4].
cond day documented torsades de pointes.
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[ig. 3. Clinical course of the case. ECG, electrocardiogram; PAF, paroxysmal atrial
brillation; TdP, torsades de pointes.
Activation of acetylcholine receptors opens voltage-dependent
alcium ion channels and increases intracellular calcium ion con-
entration. The rise in intracellular calcium ion concentration can
ontribute to enhanced automaticity or early afterdepolarization
ollowing prolongation of action potential duration and trigger
entricular tachyarrhythmias. Elevated calcium ion concentration
an also depress conduction and elicit reentry. Reentry depends
n prolongation of repolarization and is manifested either as
entricular tachycardia or ventricular ﬁbrillation.
The beat-to-beat alterations in duration and amplitude of action
otential are a consistent precursor to ventricular ﬁbrillation in
ptical mapping studies using detailed measurements of conduc-
ion and refractoriness. Tp–Te is associated with the transmural
ispersion of repolarization, which is related to the vulnerability
o ventricular arrhythmias. A prolonged Tp–Te interval caused by
n increased transmural dispersion of repolarization has potential
rrhythmogenic effects. In this case, Tp–Te interval on admission,
uring administration of donepezil, was prolonged, compared to
hat after washout of donepezil. Thus, donepezil might induce TdP
ia reentrant excitation caused by heterogeneity in action potential
uration and effective refractory period.
Risk factors promoting proarrhythmia are old age, female
ex, electrolyte imbalance (hypokalemia, hypomagnesemia, or
ypocalcemia), bradycardia, atrial arrhythmias (atrial ﬁbrillation
nd ﬂutter), ischemic heart disease, congestive heart failure, over-
ose of a drug, rapid rate of intravenous infusion with a drug, use of
ther drugs that prolong QT interval directly or indirectly, a family
istory of sudden death, congenital long QT syndrome, and poly-
orphisms of genes coding ion channels or enzymes involved in
rug metabolism [1].
Our patient had multiple risk factors for TdP: increasing age,
emale sex, and paroxysmal atrial ﬁbrillation. Coronary arteri-
gram demonstrated no ischemic heart disease and we thought
hat ischemia was not involved in this arrhythmic event. Because
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QTc interval was normal throughout hospitalization, we  did not
investigate the genetic analysis of congenital long QT syndrome.
Some factors inducing speciﬁc gene mutations and selective
action potential prolongation may  lead to a proarrhythmic state
precipitating the onset of QT prolongation and TdP [5,6]. This
indicates that there are individual speciﬁcities and differences in
sensitivity to the drug, and gene abnormalities are assumed behind
these differences.
Unlike in previous reports [2], QT prolongation, hypokalemia,
and bradycardia were absent in our case. QT prolongation is a pre-
dictor of fatal ventricular arrhythmia and sudden death. The risk
of TdP increases with increasing length of QTc interval, but the
relationship is not linear. It is important to emphasize that QT pro-
longation is only a surrogate marker or signal of arrhythmic risk
and not the risk itself.
An implantable cardioverter deﬁbrillator (ICD) terminates ven-
tricular tachycardia and ventricular ﬁbrillation, and reduces the
rate of sudden cardiac death [7,8]. There was  no indication for ICD
implantation in the present case.
In conclusion, this case suggests that donepezil may cause
life-threatening ventricular arrhythmias without QT prolongation.
Caution is needed for symptoms, such as dizziness, palpitation, or
syncope, which could indicate cardiac arrhythmias in any patient
prescribed donepezil. Even if QTc interval is normal in patients
taking donepezil and experiencing symptoms associated with TdP,
electrocardiographic monitoring is recommended.
Conﬂict of interest
Authors declare no conﬂict of interest.
References
1] Kerin NZ, Somberg J. Proarrhythmia deﬁnition, risk factors, causes, treatment,
and controversies. Am Heart J 1994;128:575–85.
2] Takaya T, Okamoto M,  Yodoi K, Hata K, Kijima Y, Nakajima H, Nishikawa Y, Kita
T,  Ito M,  Seo T, Kawashima S. Torsades de pointes with QT prolongation related
to  donepezil use. J Cardiol 2009;54:507–11.
3] Isik AT, Yildiz GB, Bozoglu E, Yay A, Aydemir E. Cardiac safety of donepezil in
elderly patients with Alzheimer disease. Intern Med 2012;51:575–8.
4] Omiya T, Shimizu A, Ueyama T, Yoshiga Y, Doi M,  Hiratsuka A, Fukuda M,  Yoshida
M,  Matsuzaki M.  Effects of isoproterenol and propranolol on the inducibility and
frequency of ventricular ﬁbrillation in patients with Brugada syndrome. J Cardiol
2012;60:47–54.
5] Ito S, Taketani T, Sugamori T, Okada T, Sato H, Adachi T, Takeda M,  Kodani N,
Takahashi N, Endo A, Yoshitomi H, Tanabe K, Shimizu W.  A case of long QT
syndrome having compound mutations of KCNH2 and SCN5A. J Cardiol Case
2012;6:e166–9.
6] Morita H. The compound mutation, a model for acquire long QT syndrome. J
Cardiol Case 2012;6:e187.
7] Hadano Y, Ogawa H, Wakeyama T, Takaki A, Iwami T, Kimura M,  Miyazaki Y,
Okada H, Shimizu A, Matsuzaki M.  Deﬁbrillation efﬁcacy of a subcutaneous array
lead: a case report. J Cardiol Case 2010;1:e21–4.
8] Marsico F, Savarese G, Sardu C, D’Ascia C, Ruggiero D, Casaretti L, Parisi V, Musella
F,  Pirozzi E, Formisano R, Losco T, Filardi PP. Implantable cardioverter deﬁbrilla-
tor to prevent sudden cardiac death in a patient with systemic sclerosis: a clinical
case. J Cardiol Case 2012;5:e166–70.
